706. An Ad Hoc Subgroup Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of Fecal Microbiota, Live-jslm in Participants With Recurrent Clostridioides difficile Infection and Renal Impairment

BACKGROUND: Patients with renal comorbidity are at risk of severe Clostridioides difficile infection (CDI) and recurrence. Fecal microbiota, live-jslm (REBYOTA™, abbreviated here as RBL, previously known as RBX2660) is the first FDA-approved, microbiota-based live biotherapeutic for the prevention o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fischer, Monika, Thul, Joan, Guthmueller, Beth, Sandrock, Christian, Van Hise, Nicholas, Tillotson, Glenn S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677773/
http://dx.doi.org/10.1093/ofid/ofad500.768

Ejemplares similares

Ejemplares similares